Mecasermin Recruiting Phase 2 Trials for Phelan-McDermid Syndrome / 22q13 Deletion Syndrome Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01525901Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)